Patents Assigned to Dicerna Pharmaceuticals, Inc.
  • Methods for treating hepatitis B infection
    Patent number: 11052104
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Methods for treating hepatitis B infection
    Patent number: 11052105
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Beta catenin nucleic acid inhibitor molecule
    Patent number: 11008571
    Abstract: Provided herein is a potent, optimized ?-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides. Also provided are methods and compositions for reducing ?-catenin expression and methods and compositions for treating cancer.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: May 18, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Shanthi Ganesh
  • Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
    Patent number: 10954517
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 23, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Extended dicer substrate agents and methods for the specific inhibition of gene expression
    Patent number: 10870849
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 22, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob Dale Brown
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 10844381
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 24, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Extended dicer substrate agents and methods for the specific inhibition of gene expression
    Patent number: 10837013
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 17, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob Dale Brown
  • Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
    Patent number: 10821112
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 3, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Shanthi Ganesh
  • Methods for treating hepatitis B infection
    Patent number: 10799524
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 13, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
    Patent number: 10752899
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: August 25, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob D. Brown
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 10738311
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 11, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
    Patent number: 10689647
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Compositions and methods for inhibiting HMGB1 expression
    Patent number: 10675295
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
    Patent number: 10676742
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of ?-catenin by double-stranded RNA
    Patent number: 10612023
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 7, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA
    Publication number: 20200002705
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: August 20, 2019
    Publication date: January 2, 2020
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF APLHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20190390198
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 26, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 10487330
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: November 26, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 10465195
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: November 5, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20190323014
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 24, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai